Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

trastuzumab deruxtecan

Details

Files
Generic Name:
trastuzumab deruxtecan
Project Status:
Active
Therapeutic Area:
Gastric or gastroesophageal junction (GEJ) adenocarcinoma
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Enhertu
Project Line:
Reimbursement Review
Project Number:
PC0367-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Enhertu (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Enhertu (trastuzumab deruxtecan) as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open06-Aug-24
Call for patient/clinician input closed27-Sep-24
Submission received16-Sep-24
Clarification:

Eligible for consideration as a time-limited recommendation

Submission accepted01-Oct-24
Review initiated02-Oct-24
Draft CADTH review report(s) provided to sponsor for comment17-Dec-24
Deadline for sponsors comments03-Jan-25
CADTH review report(s) and responses to comments provided to sponsor31-Jan-25
Expert committee meeting (initial)12-Feb-25
Draft recommendation issued to sponsorFebruary 25, 2025
To
February 27, 2025
Draft recommendation posted for stakeholder feedback06-Mar-25
End of feedback period21-Mar-25

Files

Patient and Clinician Group Input View PDF
Last Updated : January 22, 2025